Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice

Clinical and Vaccine Immunology

Volumn 14, Issue 7, 2007, Pages 894-901

  Hu, Hui ^a,b   Lu, Xinya ^a,b   Tao, Ling ^a,b   Bai, Bingke ^a,b   Zhang, Zhenfeng ^a   Chen, Yao ^a   Zheng, Fangliang ^a   Chen, Jianjun ^a   Chen, Ze ^a   Wang, Hanzhong ^a  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; VITRONECTIN; IMMUNOGLOBULIN G; LIVE VACCINE; MEMBRANE PROTEIN; SPIKE GLYCOPROTEIN, CORONAVIRUS; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS DNA; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CORONAVIRUS; DRUG POTENTIATION; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; SALMONELLA ENTERICA; SEVERE ACUTE RESPIRATORY SYNDROME; T LYMPHOCYTE; TH1 CELL; TH2 CELL; ANIMAL; ANIMAL MODEL; BAGG ALBINO MOUSE; BLOOD; CD8+ T LYMPHOCYTE; COMPARATIVE STUDY; GENETICS; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; SALMONELLA TYPHIMURIUM; SARS CORONAVIRUS;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; ELECTROPORATION; FEMALE; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; INTERLEUKIN-2; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; SALMONELLA TYPHIMURIUM; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; TH1 CELLS; TH2 CELLS; VACCINES, ATTENUATED; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 35748964428     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00019-07     Document Type: Article

References (48)

1. Ashby, D., I. Leduc, W. Lauzon, B. C. Lee, N. Sinqhal, and D. W. Cameron. 2005. Attenuated Salmonella typhimurium SL3261 as a vaccine vector for recombinant antigen in rabbits. J. Immunol. Methods 299:153-164.
2. Barouch, D. H., A. Craiu, M. J. Kuroda, J. E. Schmitz, X. X. Zheng, S. Santra, J. D. Frost, G. R. Krivulka, M. A. Lifton, C. L. Crabbs, G. Heidecker, H. C. Perry, M. E. Davies, H. Xie, C. E. Nickerson, T. D. Steenbeke, C. I. Lord, D. C. Montefiori, T. B. Strom, J. W. Shiver, M. G. Lewis, and N. L. Letvin. 2000. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc. Natl. Acad. Sci. USA 97:4192-4197.
3. + T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J. Immunol. 168:562-568.
4. Benyacoub, J., S. Hopkins, A. Potts, S. Kelly, J. P. Kraehenbühl, R. Curtiss, P. De Grandi, and D. N. Haefliger. 1999. The nature of the attenuation of Salmonella typhimurium strains expressing human papillomavirus type 16 virus-like particles determines the systemic and mucosal antibody responses in nasally immunized mice. Infect. Immun. 67:3674-3679.
5. Caruso, A., S. Licenziati, M. Corulli, A. D. Canaris, M. A. De Francesco, S. Fiorentini, L. Peroni, F. Fallacara, F. Dima, A. Balsari, and A. Turano. 1997. Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. Cytometry 27:71-76.
6. Chou, C. F., S. Shen, Y. J. Tan, B. C. Fielding, T. H. Tan, J. Fu, Q. Xu, S. G. Lim, and W. Hong. 2005. A novel cell-based binding assay system reconstituting interaction between SARS-CoV S protein and its cellular receptor. J. Virol. Methods 123:41-48.
7. Chow, Y. H., B. L. Chiang, Y. L. Lee, W. K. Chi, W. C. Lin, Y. T. Chen, and M. H. Tao. 1998. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J. Immunol. 160:1320-1329.
8. Chow, Y. H., W. L. Huang, W. K. Chi, Y. D. Chu, and M. H. Tao. 1997. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J. Virol. 71:169-178.
9. Christian, M. D., S. M. Poutanen, and M. R. Loutfy. 2004. Severe acute respiratory syndrome. Clin. Infect. Dis. 38:1420-1427.
10. Darji, A., S. Zur Lage, A. I. Garbe, T. Chakraborty, and S. Weiss. 2000. Oral delivery of DNA vaccines using attenuated Salmonella typhimurium as carrier. FEMS Immunol. Med. Microbiol. 27:341-349.
11. Devico, A. L., T. R. Fouts, M. T. Shata, R. Kamin-Lewis, G. K. Lewis, and D. M. Hone. 2002. Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1. Vaccine 20:1968-1974.
12. Dougan, G., C. E. Hormaeche, and D. J. Maskell. 1987. Live oral Salmonella vaccines: potential use of attenuated strains as carriers of heterologous antigens to the immune system. Parasite Immunol. 9:151-160.
13. Drosten, C., S. Günther, W. Preiser, S. van der Werf, H.-R. Brodt, and S. Becker. 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348:1967-1976.
14. Farrar, W. L., H. M. Johnson, and J. J. Farrar. 1981. Regulation of the production of immune interferon and cytotoxic T lymphocytes by interleukin-2. J. Immunol. 126:1120-1125.
15. Feltquate, D. M., S. Heaney, R. G. Webster, and H. L. Robinson. 1997. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J. Immunol. 158:2278-2284.
16. Flo, J., S. Tisminetzky, and F. Baralle. 2001. Oral transgene vaccination mediated by attenuated salmonellae is an effective method to prevent herpes simplex virus-2 induced disease in mice. Vaccine 19:1772-1782.
17. Froebel, K. S., N. G. Pakker, F. Aiuti, M. Bofill, H. Choremi-Papadopoulou, J. Economidou, and C. Rabian. 1999. Standardization and quality assurance of lymphocyte proliferation assays for use in the assessment of immune function. J. Immunol. Methods 227:85-97.
18. Geissler, M., A. Gesien, K. Tokushige, and J. R. Wands. 1997. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J. Immunol. 158:1231-1237.
19. Harrison, J. A., B. Villarreal-Ramos, P. Mastroeni, R. Demarco de Hormaeche, and E. Hormaeche. 1997. Correlates of protection induced by live Aro-Salmonella typhimurium vaccines in the murine typhoid model. Immunology 90:618-625.
20. Hofmann, H., K. Hattermann, A. Marzi, G. Thomas, M. Geier, M. Krumbiegel, S. Kuate, K. Uberla, M. Niedrig, and S. Pohlmann. 2004. S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J. Virol. 78:6134-6142.
21. Ho, T.-Y., S.-L. Wu, S.-E. Cheng, Y.-C. Wei, S. P. Huang, and C.-Y. Hsiang. 2004. Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein. Biochem. Biophys. Res. Commun. 313:938-947.
22. + T cell immune responses. Vaccine 24:4905-4913.
23. Kawase, I., C. G. Brooks, K. Kuribayashi, W. Newman, and C. S. Henney. 1983. Interleukine-2 induces gamma-interferon production: participation of macrophages and NK-like cells. J. Immunol. 131:288-292.
24. Kim, J. J., J. S. Yang, K. Dang, K. H. Manson, and D. B. Weiner. 2001. Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants. Clin. Cancer Res. 7:882s-889s.
25. Kong, W. P., L. Xu, S. Konrad, K. Stadler, J. B. Ulmer, S. Abrignani, R. Rappuoli, and G. J. Nabel. 2005. Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization. J. Virol. 11:13915-13923.
26. Kuhnle, G., R. A. Collins, J. E. Scott, and G. M. Keil. 1996. Bovine interleukins 2 and 4 expressed in recombinant bovine herpesvirus 1 are biologically active secreted glycoproteins. J. Gene Virol. 77:2231-2240.
27. Moore, A. C., W. P. Kong, B. K. Chakrabarti, and J. N. Gary. 2002. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. J. Virol. 76:243-250.
28. Nobiron, I., I. Thompson, J. Brownlie, and M. E. Collins. 2001. Cytokine adjuvancy of BVDV DNA vaccine enhances both humoral and cellular immune responses in mice. Vaccine 19:4226-4235.
29. Peiris, J. S. M., S. T. Lai, L. L. M. Poon, Y. Guan, L. Y. C. Yam, W. Lim, J. Nicholls, W. K. S. Yee, W. W. Yan, M. T. Cheung, V. C. C. Cheng, K. H. Chan, D. N. C. Tsang, R. W. H. Yung, T. K. Ng, and K. Y. Yuen. 2003. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361:1319-1325.
30. Popova, R., and X. Zhang. 2002. The spike but not hemagglutinin/esterase protein of bovine coronavirus is necessary and sufficient for viral infection. Virology 294:6119-6125.
31. Premenko-Lanier, M., P. A. Rota, G. Rhodes, D. Verhoeven, D. H. Barouch, N. W. Lerche, N. L. Letvin, W. J. Bellini, and M. B. McChesney. 2003. DNA vaccination of infants in the presence of maternal antibody: a measles model in the primate. Virology 307:67-75.
32. Sanchez, C. M., A. Izeta, J. M. Sanchez-Morgado, S. Alonso, I. Sola, M. Balasch, and J. Plana-Duran. 1999. Targeted recombination demonstrates that the spike gene of transmissible gastroenteritis coronavirus is a determinant of enteric tropism and virulence. J. Virol. 73:7607-7618.
33. Simmons, G., J. D. Reeves, A. J. Rennekamp, S. M. Amberg, A. J. Piefer, and P. Bates. 2004. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS CoV) spike glycoprotein-mediated viral entry. Proc. Natl. Acad. Sci. USA 101:4240-4245.
34. Sin, J.-I., J. J. Kim, J. D. Boyer, R. B. Ciccarelli, and T. J. Higgins. 1999. In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. J. Virol. 73:501-509.
35. Sirard, J. C., F. Niedergang, and J. P. Kraehenbuhl. 1999. Live attenuated salmonella: a paradigm of mucosal vaccine. Immunol. Rev. 171:5-26.
36. Song, K., Y. Chang, and G. J. Prud'homme. 2000. Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer. Gene Ther. 7:481-492.
37. Stadler, K., V. Masignani, M. Eickmann, S. Becker, S. Abrignani, H. D. Klenk, and R. Rappuoli. 2003. SARS - beginning to understand a new virus. Nat. Rev. Microbiol. 1:209-218.
38. Torres, J. M., C. Sanchez, C. Sune, C. Smerdou, L. Prevec, F. Graham, and L. Enjuanes. 1995. Induction of antibodies protecting against transmissible gastroenteritis coronavirus (TGEV) by recombinant adenovirus expressing TGEV spike protein. Virology 213:503-516.
39. Wang, Y. D., W. Y. Sin, G. B. Xu, H. H. Yang, T. Y. Wong, X. W. Pang, X. Y. He, H. G. Zhang, J. N. Ng, C. S. Cheng, J. Yu, L. Meng, R. F. Yang, S. T. Lai, Z. H. Guo, Y. Xie, and W. F. Chen. 2004. T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus spike protein elicit a specific T-cell immune response in patients who recovered from SARS. J. Virol. 78: 5612-5618.
40. Weyand, C. M., J. Goronzy, M. J. Dallman, and C. G. Fathman. 1986. Administration of recombinant interleukin 2 in vivo induces a polyclonal IgM response. J. Exp. Med. 163:1607-1612.
41. Wong, H. T., S. C. Cheng, F. W. Sin, E. W. Chan, Z. T. Sheng, and Y. Xie. 2002. A DNA vaccine against foot-and-mouth disease elicits an immune response in swine which is enhanced by co-administration with interleukin-2. Vaccine 20:2641-2647.
42. Woo, P. C., S. K. Lau, H. W. Tsoi, Z. W. Chen, B. H. Wong, L. Zhang, J. K. Chan, L. P. Wong, W. He, C. Ma, K. H. Chan. D. D. Ho, and K. Y. Yuen. 2005. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. Vaccine 23:4959-4968.
43. Woo, P. C., L. P. Wong, B. J. Zheng, and Y. K. Yuen. 2001. Unique immunogenicity of hepatitis B virus DNA vaccine presented by live-attenuated Salmonella typhimurium. Vaccine 19:2945-2954.
44. Yang, Z. Y., W. P. Kong, Y. Huang, A. Roberts, B. R. Murphy, K. Subbarao, and G. J. Nabel. 2004. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428:561-564.
45. Zakhartchouk, A. N., Q. Liu, M. Petric, and L. A. Babiuk. 2005. Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines. Vaccine 23:4385-4391.
46. Zhang, H., G. Wang, J. Li, Y. Nie, X. Shi, G. Lian, W. Wang, X. Yin, Y. Zhao, X. Qu, M. Ding, and H. Deng. 2004. Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies. J. Virol. 78:6938-6945.
47. Zheng, B. J., P. C. Woo, M. Ng, H. Tsoi, L. Wong, and K. Yuen. 2001. A crucial role of macrophages in the immune responses to oral DNA vaccination against hepatitis B virus in a murine model. Vaccine 20:140-147.
48. Zucchelli, S., S. Capone, E. Fattori, A. Folgori, A. Di Marco, D. Casimiro, A. J. Simon, R. Laufer, N. La Monica, R. Cortese, and A. Nicosia. 2000. Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer. J. Virol. 74:11598-11607.